Effects of an Exercise and Nutritional Intervention on Circulating Biomarkers and Metabolomic Profiling During Adjuvant Treatment for Localized Breast Cancer: Results From the PASAPAS Feasibility Randomized Controlled Trial.


Journal

Integrative cancer therapies
ISSN: 1552-695X
Titre abrégé: Integr Cancer Ther
Pays: United States
ID NLM: 101128834

Informations de publication

Date de publication:
Historique:
entrez: 3 3 2021
pubmed: 4 3 2021
medline: 12 10 2021
Statut: ppublish

Résumé

Exercise has been shown to improve physical and psychological conditions during cancer therapy, but mechanisms remain poorly understood. The purpose of the present study was to report the results of cancer-related biomarkers and metabolomics outcomes from the PASAPAS feasibility study. In the PASAPAS randomized controlled trial, 61 women beginning adjuvant chemotherapy for localized breast cancer were randomized in a 6-month program of weekly aerobic exercises associated with nutritional counseling versus usual care with nutritional counseling. In the present analysis of 58 women for whom blood samples were available, first, circulating levels of biomarkers (ie, insulin, insulin-like growth factor 1, estradiol, adiponectin, leptin, interleukin-6, and tumor necrosis factor α) were measured at baseline and 6-month follow-up. Changes in biomarkers were compared between exercisers (n = 40) and controls (n = 18) using mixed-effect models. Second, serum metabolites were studied using an untargeted Over the 6-month intervention, no statistically significant differences were observed between exercisers and controls regarding changes in biomarkers and metabolomic profiles. The present analysis of the PASAPAS feasibility trial did not reveal any improvement in circulating biomarkers nor identified metabolic signatures in exercisers versus controls during adjuvant breast cancer treatment. Larger studies preferably in women with poor physical activity level to avoid ceiling effect, testing different doses and types of exercise on additional biological pathways, could allow to clarify the mechanisms mediating beneficial effects of physical exercise during cancer treatment. ClinicalTrials.gov Identifier: NCT01331772. Registered 8 April 2011, https://clinicaltrials.gov/ct2/show/NCT01331772?term=pasapas&rank=1.

Identifiants

pubmed: 33655799
doi: 10.1177/1534735420977666
pmc: PMC7934026
doi:

Substances chimiques

Biomarkers, Tumor 0

Banques de données

ClinicalTrials.gov
['NCT01331772']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1534735420977666

Références

Int J Cancer. 2020 Jan 1;146(1):150-160
pubmed: 31173341
Int J Cancer. 2013 Mar 1;132(5):1191-200
pubmed: 22847383
Oncotarget. 2017 Jun 28;8(48):83570-83584
pubmed: 29137365
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
Int J Biol Markers. 2007 Jul-Sep;22(3):186-93
pubmed: 17922461
BMJ Open. 2013 Oct 28;3(10):e003855
pubmed: 24165030
BMC Med Res Methodol. 2013 Aug 20;13:104
pubmed: 23961782
Breast Cancer Res Treat. 2017 Apr;162(3):399-408
pubmed: 28138894
Int J Epidemiol. 2016 Oct;45(5):1433-1444
pubmed: 27073263
J Clin Oncol. 2009 Jul 20;27(21):3437-44
pubmed: 19470939
Mol Clin Oncol. 2016 May;4(5):893-897
pubmed: 27123303
J Neuroimmunol. 2016 Dec 15;301:74-82
pubmed: 27890459
CA Cancer J Clin. 2012 Jul-Aug;62(4):243-74
pubmed: 22539238
Int J Cancer. 2019 Jul 15;145(2):360-369
pubmed: 30614528
J Clin Endocrinol Metab. 2005 Nov;90(11):5970-7
pubmed: 16091494
PLoS One. 2016 Oct 14;11(10):e0164877
pubmed: 27741291
Cancer Causes Control. 2009 Oct;20(8):1523-8
pubmed: 19434504
Cochrane Database Syst Rev. 2016 Sep 21;9:CD005001
pubmed: 27650122
Community Oncol. 2010 Oct;7(10):463-471
pubmed: 21274408
Mol Oncol. 2015 Jan;9(1):128-39
pubmed: 25151299
Ann Oncol. 2013 Feb;24(2):291-300
pubmed: 23041586
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1009-17
pubmed: 27197276
Maturitas. 2016 Mar;85:104-11
pubmed: 26857888
Medicine (Baltimore). 2020 May;99(20):e20231
pubmed: 32443355
Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):355-365
pubmed: 27742668
Support Care Cancer. 2019 Sep;27(9):3449-3461
pubmed: 30680617
BMC Sports Sci Med Rehabil. 2016 Apr 19;8:10
pubmed: 27099757
Mol Oncol. 2012 Aug;6(4):437-44
pubmed: 22687601
Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):329-37
pubmed: 26853341
J Clin Oncol. 2011 Jan 1;29(1):32-9
pubmed: 21115858
Am J Transl Res. 2020 Jun 15;12(6):3046-3056
pubmed: 32655829
Int J Behav Nutr Phys Act. 2006 Mar 31;3:7
pubmed: 16579852
Breast Cancer Res. 2018 Aug 2;20(1):81
pubmed: 30071893
Breast Cancer Res Treat. 2018 Apr;168(2):421-431
pubmed: 29235043
Acta Oncol. 2015 May;54(5):635-54
pubmed: 25752971
Int J Cancer. 2003 Feb 20;103(5):642-6
pubmed: 12494472
J Physiother. 2016 Apr;62(2):68-82
pubmed: 26996098
Cancer Lett. 2014 Feb 1;343(1):33-41
pubmed: 24041867
Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):614-20
pubmed: 18323413
J Clin Oncol. 2018 Mar 20;36(9):875-883
pubmed: 29356607
Front Physiol. 2020 Feb 13;11:91
pubmed: 32116795
J Phys Act Health. 2011 Aug;8(6):858-65
pubmed: 21832302
Cancer. 2016 Sep 1;122(17):2646-53
pubmed: 27219902
Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):477-81
pubmed: 9641491
BMC Cancer. 2016 Aug 25;16(1):682
pubmed: 27562357
Cancer Nurs. 2020 Mar/Apr;43(2):115-125
pubmed: 30601270

Auteurs

Olivia Febvey-Combes (O)

Léon Bérard Cancer Center, Lyon, France.

Elodie Jobard (E)

Léon Bérard Cancer Center, Lyon, France.
University of Lyon, Villeurbanne, France.

Adrien Rossary (A)

University of Clermont Auvergne, Clermont-Ferrand, France.

Vincent Pialoux (V)

University of Lyon, Villeurbanne, France.
Institut Universitaire de France, Paris, France.

Aude-Marie Foucaut (AM)

Paris 13 University, Paris, France.

Magali Morelle (M)

Léon Bérard Cancer Center, Lyon, France.

Lidia Delrieu (L)

Léon Bérard Cancer Center, Lyon, France.
University of Lyon, Villeurbanne, France.

Agnès Martin (A)

University of Lyon, Villeurbanne, France.

Florence Caldefie-Chézet (F)

University of Clermont Auvergne, Clermont-Ferrand, France.

Marina Touillaud (M)

Léon Bérard Cancer Center, Lyon, France.
Inserm UA8, Lyon, France.

Sophie E Berthouze (SE)

University of Lyon, Villeurbanne, France.

Houda Boumaza (H)

University of Lyon, Villeurbanne, France.

Bénédicte Elena-Herrmann (B)

University of Lyon, Villeurbanne, France.
Grenoble Alpes University, Grenoble, France.

Patrick Bachmann (P)

Léon Bérard Cancer Center, Lyon, France.

Olivier Trédan (O)

Léon Bérard Cancer Center, Lyon, France.

Marie-Paule Vasson (MP)

University of Clermont Auvergne, Clermont-Ferrand, France.
Clermont-Ferrand University Hospital, Jean Perrin Cancer Center, Clermont-Ferrand, France.

Béatrice Fervers (B)

Léon Bérard Cancer Center, Lyon, France.
Inserm UA8, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH